Literature DB >> 12463765

CpG DNA in the prevention and treatment of infections.

Alexander Dalpke1, Stefan Zimmermann, Klaus Heeg.   

Abstract

Microbial infection is sensed by Toll-like receptors (TLRs) on innate immune cells. Among the ten so far defined TLRs, TLR9 and its ligand are peculiar. TLR9 recognises bacterial DNA characterised by the abundance of unmethylated CpG dinucleotides, which distinguish bacterial DNA (CpG DNA) from mammalian DNA. Moreover, TLR9 shows a restricted cellular and subcellular pattern of expression. In contrast to other TLR agonists, CpG DNA is superior in activation of dendritic dells and induction of costimulatory cytokines such as interleukin (IL)-12 and IL-18. This qualifies CpG DNA as a Th1-promoting adjuvant. During infection, recognition of CpG DNA of intracellular pathogens skews and fine-tunes the ongoing immune response and induces long-lasting Th1 milieus. Thus, CpG DNA might play an important role in driving the immune system to a Th1 profile, preventing undesired Th2 milieus that might favour induction of allergic responses. Since CpG DNA can be synthesised with high purity and sequence fidelity, synthetic CpG DNA will become an important agent for Th1 instruction and be an effective adjuvant during vaccination.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12463765     DOI: 10.2165/00063030-200216060-00003

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


  9 in total

Review 1.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 2.  Immune modulatory oligonucleotides in the prevention and treatment of allergen-induced eustachian tube dysfunction in the animal model.

Authors:  Deidra A Blanks; Charles S Ebert
Journal:  Curr Allergy Asthma Rep       Date:  2008-11       Impact factor: 4.806

3.  Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.

Authors:  Angelo Corti; Monica Giovannini; Carmen Belli; Eugenio Villa
Journal:  J Oncol       Date:  2010-06-03       Impact factor: 4.375

4.  Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7.

Authors:  Tomoko Hayashi; Howard B Cottam; Michael Chan; Guangyi Jin; Rommel I Tawatao; Brian Crain; Lisa Ronacher; Karen Messer; Dennis A Carson; Maripat Corr
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-05-14       Impact factor: 3.619

5.  Intraperitoneal prophylaxis with CpG oligodeoxynucleotides protects neutropenic mice against intracerebral Escherichia coli K1 infection.

Authors:  Sandra Ribes; Tanja Meister; Martina Ott; Sandra Redlich; Hana Janova; Uwe-Karsten Hanisch; Stefan Nessler; Roland Nau
Journal:  J Neuroinflammation       Date:  2014-01-23       Impact factor: 8.322

Review 6.  Chronic Implant-Related Bone Infections-Can Immune Modulation be a Therapeutic Strategy?

Authors:  Elisabeth Seebach; Katharina F Kubatzky
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561

7.  Role of the functional Toll-Like receptor-9 promoter polymorphism (-1237T/C) in increased risk of end-stage renal disease: a case-control study.

Authors:  Hsin-Yi Yang; Kuo-Cheng Lu; Herng-Sheng Lee; Shih-Ming Huang; Yuh-Feng Lin; Chia-Chao Wu; Donald M Salter; Sui-Lung Su
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

8.  Matrix protein CCN1 induced by bacterial DNA and CpG ODN limits lung inflammation and contributes to innate immune homeostasis.

Authors:  H-G Moon; Z Qin; T Quan; L Xie; C S Dela Cruz; Y Jin
Journal:  Mucosal Immunol       Date:  2014-07-09       Impact factor: 7.313

Review 9.  Cooperation of Oligodeoxynucleotides and Synthetic Molecules as Enhanced Immune Modulators.

Authors:  Shireen Nigar; Takeshi Shimosato
Journal:  Front Nutr       Date:  2019-08-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.